SULFABENZAMIDE


Synonyms	NSC-74587 Sulfabenzamide Sulfabenzamide (triple sulfa) Triple sulfa (sulfabenzamide)
Status
Molecule Category	UNKNOWN
UNII	G58F8OPL4I
EPA CompTox	DTXSID7045287


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	PBCZLFBEBARBBI-UHFFFAOYSA-N
Smiles	Nc1ccc(S(=O)(=O)NC(=O)c2ccccc2)cc1
InChI	InChI=1S/C13H12N2O3S/c14-11-6-8-12(9-7-11)19(17,18)15-13(16)10-4-2-1-3-5-10/h1-9H,14H2,(H,15,16)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C13H12N2O3S
Molecular Weight	276.32
AlogP	1.39
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	3.0
Polar Surface Area	89.26
Molecular species	ACID
Aromatic Rings	2.0
Heavy Atoms	19.0

Related Entries

Cross References

Resources	Reference
ChEBI	94677
ChEMBL	CHEMBL1243
DrugBank	DB09355
DrugCentral	3558
FDA SRS	G58F8OPL4I
PDB	BS4
PubChem	5319
SureChEMBL	SCHEMBL93841
ZINC	ZINC000005421253

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).